Beta Bionics (NASDAQ:BBNX) Insider Mike Mensinger Sells 2,650 Shares of Company Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the sale, the insider owned 174,740 shares of the company’s stock, valued at approximately $3,844,280. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 16th, Mike Mensinger sold 2,650 shares of Beta Bionics stock. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00.
• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $83,606.25.

Beta Bionics Price Performance

NASDAQ BBNX opened at $17.58 on Friday. The business has a fifty day moving average of $19.16 and a 200-day moving average of $14.89. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. The company had revenue of $35.51 million during the quarter. Sell-side analysts forecast that Beta Bionics, Inc. will post -2.02 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BBNX shares. Truist Financial boosted their target price on shares of Beta Bionics from $23.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday, September 24th. Wells Fargo & Company started coverage on Beta Bionics in a report on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price on the stock. Bank of America lifted their price objective on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, September 15th. Jefferies Financial Group began coverage on shares of Beta Bionics in a report on Monday, October 12th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Leerink Partners lifted their price target on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and a consensus target price of $23.69.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Third-quarter results slightly exceeded expectations. Beta Bionics reported a loss of $0.52 per share versus the consensus estimate of a $0.53 loss, while revenue of $35.51 million topped analyst expectations of roughly $34.7 million. The company also updated its 2026 guidance, though details were not provided in the available reports. Beta Bionics third-quarter results
• Positive Sentiment: Analyst support remains favorable. Stifel Nicolaus maintained its Buy rating, while other analysts have raised price targets. The consensus rating remains Moderate Buy, with an average target price of $23.69, above the recent trading level.
• Neutral Sentiment: Insider selling was relatively limited in the latest filings. Director Mark Hopman sold 821 shares for approximately $16,420, reducing his ownership by about 1.48%. Another insider, Mike Mensinger, sold 2,650 shares for $58,300. The transactions may weigh on sentiment, but represent small portions of their remaining holdings. SEC insider filing
• Negative Sentiment: Multiple law firms publicized a pending securities class action. The lawsuit covers investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. Investors have until November 3, 2026, to seek lead-plaintiff status. The repeated notices increase legal and reputational risks for Beta Bionics.
• Negative Sentiment: The allegations focus on FDA and iLet safety disclosures. Legal notices allege that the company’s filings did not fully disclose issues tied to an FDA warning and hundreds of potentially serious iLet complaints, including alleged life-threatening hypoglycemia incidents. These claims have not been proven, but possible regulatory action, litigation costs, or additional product concerns could pressure the stock. Beta Bionics securities class action notice
• Negative Sentiment: Execution risk remains an additional concern. The company has disclosed risks related to the commercial launch of its next-generation Mint patch pump, potentially clouding its growth outlook.

Institutional Trading of Beta Bionics

A number of institutional investors have recently made changes to their positions in BBNX. Legal & General Group Plc bought a new stake in Beta Bionics in the second quarter valued at approximately $62,000. The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics during the second quarter worth about $172,000. Ieq Capital LLC bought a new position in Beta Bionics in the 2nd quarter valued at about $229,000. Quantbot Technologies LP acquired a new position in shares of Beta Bionics in the 2nd quarter valued at approximately $264,000. Finally, Man Group plc acquired a new position in shares of Beta Bionics in the 2nd quarter valued at approximately $419,000.

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.